Nitric oxide(NO),a significant signaling molecule,plays essential roles in diverse physiological and pathological processes including cell senescence.Lysosomes are recognized as pivotal subcellular organelles of cellu...Nitric oxide(NO),a significant signaling molecule,plays essential roles in diverse physiological and pathological processes including cell senescence.Lysosomes are recognized as pivotal subcellular organelles of cellular senescence,whereas the influence of senescence on lysosomal NO homeostasis remains poorly understood.To explore the potential association between cellular senescence and alterations in lysosomal NO levels,herein,we developed FL-O1,a novel ratiometric fluorescent probe specifically designed for lysosomal NO detection.The probe selectively reacts with NO through the recognition unit of ophenylenediamine,forming an extended conjugated system that generates a distinct ratiometric optical signal with exceptional sensitivity(detection limit=95 nmol/L).FL-O1 exhibits versatile applications in both in vitro and in vivo contexts.It successfully visualizes exogenous and endogenous NO dynamics in live zebrafish models and enables specific monitoring of lysosomal NO levels in cellular systems.Importantly,the probe was utilized to quantitatively evaluate NO levels in senescent states of cancer and healthy cells.The results revealed two key insights:(1)Senescent cells consistently maintain higher NO concentrations compared to their non-senescent counterparts,and(2)senescent healthy cells exhibit elevated NO levels relative to senescent cancer cells.This innovative small-molecule probe represents a significant advancement in lysosomal NO imaging technology.Its unique design and capabilities provide a powerful tool for investigating the role of lysosomal NO in cellular senescence,potentially uncovering novel mechanistic insights and facilitating the development of targeted therapeutic strategies for senescence-related disorders.展开更多
Objective: to study and analyze the clinical value of exhaled nitric oxide (FeNO) in the treatment of asthmatic COPD overlap syndrome (ACOS). Methods: 30 patients with asthma COPD overlap syndrome treated from April 2...Objective: to study and analyze the clinical value of exhaled nitric oxide (FeNO) in the treatment of asthmatic COPD overlap syndrome (ACOS). Methods: 30 patients with asthma COPD overlap syndrome treated from April 2020 to April 2021 were selected as the observation group, and 30 patients with asthma entered the hospital at the same time. These patients were group A of the control group, and 30 patients with COPD entered the hospital at the same time. These patients were group B of the control group, and all patients received exhaled nitric oxide (FeNO).The test results of the three groups were compared. Results: compared with the two control groups, the respiratory indexes and laboratory indexes of the study group were significantly higher. There was significant difference between the two groups (P < 0.05). Conclusion: the detection of exhaled nitric oxide (FeNO) in patients with asthma COPD overlap syndrome can be used to judge the severity of the patient's condition, which can be popularized in clinic.展开更多
基金supported by the National Natural Science Foundation of China(Nos.22477101,22277098,and 22037002)Shaanxi Fundamental Science Research Project for Chemistry&Biology(No.22JHQ070)Key Laboratory of Myocardial Ischemia,Ministry of Education(No.KF202311)。
摘要Nitric oxide(NO),a significant signaling molecule,plays essential roles in diverse physiological and pathological processes including cell senescence.Lysosomes are recognized as pivotal subcellular organelles of cellular senescence,whereas the influence of senescence on lysosomal NO homeostasis remains poorly understood.To explore the potential association between cellular senescence and alterations in lysosomal NO levels,herein,we developed FL-O1,a novel ratiometric fluorescent probe specifically designed for lysosomal NO detection.The probe selectively reacts with NO through the recognition unit of ophenylenediamine,forming an extended conjugated system that generates a distinct ratiometric optical signal with exceptional sensitivity(detection limit=95 nmol/L).FL-O1 exhibits versatile applications in both in vitro and in vivo contexts.It successfully visualizes exogenous and endogenous NO dynamics in live zebrafish models and enables specific monitoring of lysosomal NO levels in cellular systems.Importantly,the probe was utilized to quantitatively evaluate NO levels in senescent states of cancer and healthy cells.The results revealed two key insights:(1)Senescent cells consistently maintain higher NO concentrations compared to their non-senescent counterparts,and(2)senescent healthy cells exhibit elevated NO levels relative to senescent cancer cells.This innovative small-molecule probe represents a significant advancement in lysosomal NO imaging technology.Its unique design and capabilities provide a powerful tool for investigating the role of lysosomal NO in cellular senescence,potentially uncovering novel mechanistic insights and facilitating the development of targeted therapeutic strategies for senescence-related disorders.
摘要Objective: to study and analyze the clinical value of exhaled nitric oxide (FeNO) in the treatment of asthmatic COPD overlap syndrome (ACOS). Methods: 30 patients with asthma COPD overlap syndrome treated from April 2020 to April 2021 were selected as the observation group, and 30 patients with asthma entered the hospital at the same time. These patients were group A of the control group, and 30 patients with COPD entered the hospital at the same time. These patients were group B of the control group, and all patients received exhaled nitric oxide (FeNO).The test results of the three groups were compared. Results: compared with the two control groups, the respiratory indexes and laboratory indexes of the study group were significantly higher. There was significant difference between the two groups (P < 0.05). Conclusion: the detection of exhaled nitric oxide (FeNO) in patients with asthma COPD overlap syndrome can be used to judge the severity of the patient's condition, which can be popularized in clinic.